Foresite Capital Management VI LLC
13F Reported Value
ⓘ$642.6M
Holdings
23
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Foresite Capital Management VI LLC disclosed 23 positions worth $642.6M in its Form 13F-HR for Q2 2026, led by $CGON (CG Oncology, Inc.) at 26.2% of the equity portfolio, followed by $ALMS and $SPTX. During the quarter the fund opened 8 new positions and exited 2 — including a new stake in $SPTX and a full exit from $CNTA. The portfolio is most concentrated in Healthcare (96.7% of disclosed assets). All figures are sourced directly from Foresite Capital Management VI LLC’s Form 13F-HR filing with the SEC under CIK 2013341.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 27.0#2,595
Quality
$168.4M2,369,574 sh - 7.1#2,949
Quality
$119.5M4,247,670 sh - —
Quality
$38.7M1,779,521 sh - —
Quality
$35.9M1,396,771 sh - 8.4
Quality
$32.7M879,713 sh - 26.9
Quality
$29.1M785,000 sh - —
Quality
$27.4M1,831,233 sh - —
Quality
$27.3M999,044 sh - —
Quality
$25.3M940,493 sh - —
Quality
$19.7M886,667 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 CG Oncology, Inc.$CGON | 27.0#2,595 | $168.4M | 2,369,574 |
 ALUMIS INC.$ALMS | 7.1#2,949 | $119.5M | 4,247,670 |
 Seaport Therapeutics, Inc.$SPTX | — | $38.7M | 1,779,521 |
 Denali Therapeutics Inc.$DNLI | — | $35.9M | 1,396,771 |
 Celldex Therapeutics, Inc.$CLDX | 8.4 | $32.7M | 879,713 |
 AGIOS PHARMACEUTICALS, INC.$AGIO | 26.9 | $29.1M | 785,000 |
 Corvus Pharmaceuticals, Inc.$CRVS | — | $27.4M | 1,831,233 |
 Parabilis Medicines, Inc.$PBLS | — | $27.3M | 999,044 |
 GH Research PLC$GHRS | — | $25.3M | 940,493 |
 Jade Biosciences, Inc.$JBIO | — | $19.7M | 886,667 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Foresite Capital Management VI LLC's 23 positions.
Showing top 10 of 23 holdings.
Sector Allocation
Healthcare
$621.1M
Technology
$18.3M
Financials
$3.2M
Full Holdings — Foresite Capital Management VI LLC (Q2 2026)
All 23 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $CGON | CG Oncology, Inc. | $168.4M | 26.2% | +7% | 27 |
| 2 | $ALMS | ALUMIS INC. | $119.5M | 18.6% | +0% | 7.1 |
| 3 | $SPTX | Seaport Therapeutics, Inc. | $38.7M | 6.0% | NEW | — |
| 4 | $DNLI | Denali Therapeutics Inc. | $35.9M | 5.6% | +15% | — |
| 5 | $CLDX | Celldex Therapeutics, Inc. | $32.7M | 5.1% | +178% | 8.4 |
| 6 | $AGIO | AGIOS PHARMACEUTICALS, INC. | $29.1M | 4.5% | +50% | 26.9 |
| 7 | $CRVS | Corvus Pharmaceuticals, Inc. | $27.4M | 4.3% | +0% | — |
| 8 | $PBLS | Parabilis Medicines, Inc. | $27.3M | 4.3% | NEW | — |
| 9 | $GHRS | GH Research PLC | $25.3M | 3.9% | +198% | — |
| 10 | $JBIO | Jade Biosciences, Inc. | $19.7M | 3.1% | +177% | — |
| 11 |  $HNGE | Hinge Health, Inc. | $18.3M | 2.9% | +0% | 74.9 |
| 12 |  $KYMR | Kymera Therapeutics, Inc. | $16.8M | 2.6% | +0% | 28.4 |
| 13 |  $ATAI.R1840904 | Atai Beckley N.V. | $14.5M | 2.3% | +0% | — |
| 14 |  $VSTM | Verastem, Inc. | $12.0M | 1.9% | +0% | 29.7 |
| 15 |  $BEAM | Beam Therapeutics Inc. | $11.3M | 1.8% | NEW | 34.2 |
| 16 |  $NERV | Minerva Neurosciences, Inc. | $11.0M | 1.7% | -0% | — |
| 17 |  $AVBP | ArriVent BioPharma, Inc. | $10.5M | 1.6% | NEW | — |
| 18 |  $AURA | Aura Biosciences, Inc. | $9.5M | 1.5% | NEW | — |
| 19 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $7.9M | 1.2% | +0% | 25.5 |
| 20 |  $RACC | Research Alliance Corp III | $3.2M | 0.5% | NEW | — |
| 21 |  $ZURA | Zura Bio Ltd | $2.7M | 0.4% | +0% | — |
| 22 |  $KLRA | Kailera Therapeutics, Inc. | $826,125 | 0.1% | NEW | — |
| 23 |  $IRON | Disc Medicine, Inc. | $70,946 | 0.0% | NEW | — |
New Positions (8)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Foresite Capital Management VI LLC including:
Track Foresite Capital Management VI LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Foresite Capital Management VI LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Foresite Capital Management VI LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Foresite Capital Management VI LLC (SEC CIK: 2013341), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Foresite Capital Management VI LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.